

NOREPINEPHRINE BITARTRATE- norepinephrine bitartrate injection
HF Acquisition Co LLC, DBA HealthFirst

NOREPINEPHRINE BITARTRATE INJECTION, USP 4mg PER 4mL (1 mg/mL)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use NOREPINEPHRINE BITARTRATE INJECTION, USP safely and effectively. See full prescribing information for NOREPINEPHRINE BITARTRATE INJECTION, USP.

NOREPINEPHRINE BITARTRATE INJECTION, USP for intravenous use Initial U.S.
Approval: 1950

INDICATIONS AND USAGE

Norepinephrine Bitartrate Injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states. (1)

DOSAGE AND ADMINISTRATION

Initial dose of 0.25 mL to 0.375 mL (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low to normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation of vital organs. (2.2)
The average maintenance dose ranges from 0.0625 mL to 0.125 mL per minute (from 2 mcg to 4 mcg of base). (2.2)

DOSAGE FORMS AND STRENGTHS

Injection: 4 mg/4 mL (1 mg/mL) norepinephrine base in single-dose glass vial. (3)

CONTRAINDICATIONS

None. (4) (4)

WARNINGS AND PRECAUTIONS

Tissue Ischemia: Avoid extravasation of Norepinephrine Bitartrate Injection into the tissues, as local necrosis might ensue due to the vasoconstrictive action of the drug. Infuse Norepinephrine Bitartrate Injection into a large vein. To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of an adrenergic blocking agent. (5.1)

Hypotension After Abrupt Discontinuation: Sudden cessation of the infusion rate may result in marked hypotension. Reduce the Norepinephrine Bitartrate Injection infusion rate gradually. (5.2)

Cardiac Arrhythmias: Norepinephrine Bitartrate Injection may cause arrhythmias. Monitor cardiac function in patients with underlying heart disease. (5.3)

Allergic Reactions with Sulfite: Norepinephrine Bitartrate Injection contains sodium metabisulfite. Sulfite may cause allergic-type-reactions. (5.4)

ADVERSE REACTIONS

Most common adverse reactions are ischemic injury, bradycardia, anxiety, transient headache, respiratory difficulty, and extravasation necrosis at injection site. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7.1)

Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7.4)

USE IN SPECIFIC POPULATIONS

Elderly patients may be at greater risk of developing adverse reactions. (8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 11/2020

TABLE OF CONTENTS

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosage and Administration Instructions

2.2 Dosage

2.3 Preparation of Diluted Solution

2.4 Drug Incompatibilities

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Tissue Ischemia

5.2 Hypotension after Abrupt Discontinuation

5.3 Cardiac Arrhythmias

5.4 Allergic Reactions Associated with Sulfite

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

7.1 MAO-Inhibiting Drugs

7.2 Tricyclic Antidepressants

7.3 Antidiabetics

7.4 Halogenated Anesthetics

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility

16 HOW SUPPLIED

17 PATIENT COUNSELING INFORMATION

*

Sections or subsections omitted from the full prescribing information are not listed.

1 INDICATIONS & USAGE

Norepinephrine Bitartrate Injection, USP is indicated to raise blood pressure in adult patients with severe, acute hypotension.

2 DOSAGE & ADMINISTRATION

2.1 Important Dosage and Administration Instructions

Correct Hypovolemia

Address hypovolemia before initiation of Norepinephrine Bitartrate Injection therapy. If the patient does not respond to therapy, suspect occult hypovolemia [see WARNINGS AND PRECAUTIONS (5.1)].

Administration

Dilute Norepinephrine Bitartrate Injection prior to use [see DOSAGE AND ADMINISTRATION (2.3)].

Infuse Norepinephrine Bitartrate Injection into a large vein. Avoid infusions into the veins of the leg in the elderly or in patients with occlusive vascular disease of the legs [see WARNINGS AND PRECAUTIONS (5.1)]. Avoid using a catheter-tie-in technique.

Discontinuation

When discontinuing the infusion, reduce the flow rate gradually. Avoid abrupt withdrawal.

2.2 Dosage

After an initial dosage of 8 to 12 mcg per minute via intravenous infusion, assess patient response and adjust dosage to maintain desired hemodynamic effect. Monitor blood pressure every two minutes until the desired hemodynamic effect is achieved, and then monitor blood pressure every five minutes for the duration of the infusion.

Typical maintenance intravenous dosage is 2 to 4 mcg per minute.

2.3 Preparation of Diluted Solution

Visually inspect Norepinephrine Bitartrate Injection for particulate matter and discoloration prior to administration (the solution is colorless). Do not use the solution if its color is pinkish or darker than slightly yellow or if it contains a precipitate.

Add the content of one Norepinephrine Bitartrate Injection vial (4 mg in 4 mL) to 1,000 mL of 5% Dextrose Injection, USP or Sodium Chloride Injection solutions that contain 5% dextrose to produce a 4 mcg per mL dilution. Dextrose reduces loss of potency due to

oxidation. Administration in saline solution alone is not recommended.

Use higher concentration solutions in patients requiring fluid restriction. Prior to use, store the diluted Norepinephrine Bitartrate Injection solution for up to 24 hours at room temperature [20°C to 25°C (68°F to 77°F)] and protect from light.

2.4 Drug Incompatibilities

Avoid contact with iron salts, alkalis, or oxidizing agents.

Whole blood or plasma, if indicated to increase blood volume, should be administered separately.

3 DOSAGE FORMS AND STRENGTHS

Injection: 4 mg/4 mL (1 mg/mL norepinephrine base) sterile, colorless solution in a single-dose amber glass vial.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Tissue Ischemia

Administration of Norepinephrine Bitartrate Injection to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating Norepinephrine Bitartrate Injection [see DOSAGE AND ADMINISTRATION (2.1)]. Avoid Norepinephrine Bitartrate Injection in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction.

Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients.

Extravasation of Norepinephrine Bitartrate Injection may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation [see DOSAGE AND ADMINISTRATION (2.1)].

Emergency Treatment of Extravasation

To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults.

Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.

5.2 Hypotension after Abrupt Discontinuation

Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the Norepinephrine Bitartrate Injection infusion rate while expanding blood volume with intravenous fluids.

5.3 Cardiac Arrhythmias

Norepinephrine Bitartrate Injection elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias.

5.4 Allergic Reactions Associated with Sulfite

Norepinephrine Bitartrate Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

Tissue Ischemia [see WARNINGS AND PRECAUTIONS (5.1)]

Hypotension [see WARNINGS AND PRECAUTIONS (5.2)]

Cardiac Arrhythmias [see WARNINGS AND PRECAUTIONS (5.3)]

The most common adverse reactions are hypertension and bradycardia.

The following adverse reactions can occur:

Nervous system disorders: Anxiety, headache

Respiratory disorders: Respiratory difficulty, pulmonary edema

7 DRUG INTERACTIONS

7.1 MAO-Inhibiting Drugs

Co-administration of Norepinephrine Bitartrate Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) can cause severe, prolonged hypertension.

If administration of Norepinephrine Bitartrate Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.

7.2 Tricyclic Antidepressants

Co-administration of Norepinephrine Bitartrate Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If administration of Norepinephrine Bitartrate Injection cannot be avoided in these patients, monitor for hypertension.

7.3 Antidiabetics

Norepinephrine Bitartrate Injection can decrease insulin sensitivity and raise blood glucose. Monitor glucose and consider dosage adjustment of antidiabetic drugs.

7.4 Halogenated Anesthetics

Concomitant use of Norepinephrine Bitartrate Injection with halogenated anesthetics (e.g., cyclopropane, desflurane, enflurane, isoflurane, and sevoflurane) may lead to ventricular tachycardia or ventricular fibrillation. Monitor cardiac rhythm in patients receiving concomitant halogenated anesthetics.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Limited published data consisting of a small number of case reports and multiple small trials involving the use of norepinephrine in pregnant women at the time of delivery have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are risks to the mother and fetus from hypotension associated with septic shock, myocardial infarction and stroke which are medical emergencies in pregnancy and can be fatal if left untreated. (see CLINICAL CONSIDERATIONS below). In animal reproduction studies, using high doses of intravenous norepinephrine resulted in lowered maternal placental blood flow. Clinical relevance to changes in the human fetus is unknown since the average maintenance dose is ten times lower (see DATA below).

Increased fetal reabsorptions were observed in pregnant hamsters after receiving daily injections at approximately 2 times the maximum recommended dose on a mg/m³ basis for four days during organogenesis (see DATA below).

The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2-4% and 15–20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Hypotension associated with septic shock, myocardial infarction, and stroke are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic shock, myocardial infarction and stroke may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of norepinephrine on the fetus.

Data

Animal Data

A study in pregnant sheep receiving high doses of intravenous norepinephrine (40 mcg/min, at approximately 10 times the average maintenance dose of 2-4 mcg/min in human, on a mg/kg basis) exhibited a significant decrease in maternal placental blood

flow. Decreases in fetal oxygenation, urine and lung liquid flow were also observed.

Norepinephrine administration to pregnant rats on Gestation Day 16 or 17 resulted in cataract production in rat fetuses.

In hamsters, an increased number of resorptions (29.1% in study group vs. 3.4% in control group), fetal microscopic liver abnormalities and delayed skeletal ossification were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a mg/m² basis at a maternal subcutaneous dose of 0.5 mg/kg/day from Gestation Day 7-10).

8.2 Lactation

Risk Summary

There are no data on the presence of norepinephrine in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. Clinically relevant exposure to the infant is not expected based on the short half-life and poor oral bioavailability of norepinephrine.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

Clinical studies of Norepinephrine Bitartrate Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Avoid administration of Norepinephrine Bitartrate Injection into the veins in the leg in elderly patients [see WARNINGS AND PRECAUTIONS (5.1)].

10 OVERDOSAGE


Overdosage with Norepinephrine Bitartrate Injection may result in headache, severe hypertension, reflex bradycardia, marked increase in peripheral resistance, and decreased cardiac output.

In case of overdosage, discontinue Norepinephrine Bitartrate Injection until the condition of the patient stabilizes.

11 DESCRIPTION

Norepinephrine (sometimes referred to as l-arterenol/Levarterenol or l-norepinephrine) is a sympathomimetic amine which differs from epinephrine by the absence of a methyl group on the nitrogen atom.

Norepinephrine bitartrate is (-)- α -(aminomethyl)-3,4-dihydroxybenzyl alcohol tartrate (1:1) (salt) monohydrate (molecular weight 337.3 g/mol) and has the following structural formula:



Norepinephrine Bitartrate Injection is supplied in a sterile aqueous solution in the form of the bitartrate salt to be administered by intravenous infusion. Norepinephrine is sparingly soluble in water, very slightly soluble in alcohol and ether, and readily soluble in acids. Each mL contains 1 mg of norepinephrine base (equivalent to 1.89 mg of norepinephrine bitartrate, anhydrous basis), sodium chloride for isotonicity, not more than 0.2 mg (vials) of sodium metabisulfite as an antioxidant. It has a pH of 3.0 to 4.5. The air in the containers has been displaced by nitrogen gas.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).

12.2 Pharmacodynamics

The primary pharmacodynamic effects of norepinephrine are cardiac stimulation and vasoconstriction. Cardiac output is generally unaffected, although it can be decreased,

and total peripheral resistance is also elevated. The elevation in resistance and pressure result in reflex vagal activity, which slows the heart rate and increases stroke volume. The elevation in vascular tone or resistance reduces blood flow to the major abdominal organs as well as to skeletal muscle. Coronary blood flow is substantially increased secondary to the indirect effects of alpha stimulation. After intravenous administration, a pressor response occurs rapidly and reaches steady state within 5 minutes. The pharmacologic actions of norepinephrine are terminated primarily by uptake and metabolism in sympathetic nerve endings. The pressor action stops within 1-2 minutes after the infusion is discontinued.

12.3 Pharmacokinetics

Absorption

Following initiation of intravenous infusion, the steady state plasma concentration is achieved in 5 min.

Distribution

Plasma protein binding of norepinephrine is approximately 25%. It is mainly bound to plasma albumin and to a smaller extent to prealbumin and alpha 1-acid glycoprotein. The volume of distribution is 8.8 L. Norepinephrine localizes mainly in sympathetic nervous tissue. It crosses the placenta but not the blood-brain barrier.

Elimination

The mean half-life of norepinephrine is approximately 2.4 min. The average metabolic clearance is 3.1 L/min.

Metabolism

Norepinephrine is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and MAO. The major metabolites are normetanephrine and 3-methoxy-4-hydroxy mandelic acid (vanillylmandelic acid, VMA), both of which are inactive. Other inactive metabolites include 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol.

Excretion

Noradrenaline metabolites are excreted in urine primarily as sulphate conjugates and, to a lesser extent, as glucuronide conjugates. Only small quantities of norepinephrine are excreted unchanged.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility

Carcinogenesis, mutagenesis, and fertility studies have not been performed.

CLOSE

16 HOW SUPPLIED

Norepinephrine Bitartrate Injection, USP is a sterile, colorless solution for injection

intended for intravenous use. It contains the equivalent of 1 mg of norepinephrine base per 1 mL (4 mg/4 mL). It is available as 4 mg/4 mL in single-dose amber glass vials.

NOREPINEPHRINE BITARTRATE INJECTION, USP 4mg PER 4mL (1 mg/mL) is supplied in the following dosage forms.

NDC 51662-1528-1 NOREPINEPHRINE BITARTRATE INJECTION, USP 4mg PER 4mL (1 mg/mL) 4mL VIAL

NDC 51662-1528-2 NOREPINEPHRINE BITARTRATE INJECTION, USP 4mg PER 4mL (1 mg/mL) 4mL VIAL in a Pouch

NDC 51662-1528-3 NOREPINEPHRINE BITARTRATE INJECTION, USP 4mg PER 4mL (1 mg/mL) 4mL VIAL, 10 Pouches in a Case

HF Acquisition Co LLC, DBA HealthFirst
Mukilteo, WA 98275

Also supplied in the following manufacture supplied dosage forms

Supplied as:

Boxes of 10 x 4 mg/4 mL in amber glass vials (NDC 0143-9318-10)

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Store in original carton until time of administration to protect from light. Discard unused portion.

17 PATIENT COUNSELING INFORMATION

Risk of Tissue Damage

Advise the patient, family, or caregiver to report signs of extravasation urgently [see WARNINGS AND PRECAUTIONS (5.1)].

Manufactured by:

HIKMA FARMACEUTICA (PORTUGAL), S.A.

Estrada do Rio da Mo, no 8, 8A e 8B - Fervenca - 2705-906 Terrugem SNT, PORTUGAL

Distributed by:

Hikma Pharmaceuticals USA Inc.

Berkeley Heights, NJ 07922

Revised: November 2020

PIN499-WES/3

PRINCIPAL DISPLAY PANEL - 51662-1528-1 VIAL LABEL AND SERIALIZATION LABELING

NDC 0143-9318-01

Rx only

4 mL Single Dose Vial

**Norepinephrine
Bitartrate Injection, USP**

Each mL contains norepinephrine bitartrate
equal to 1 mg norepinephrine base.

**DILUTE BEFORE USE. Protect from light.
Warning: Contains Sulfites.**

**4 mg per 4 mL
(1 mg/mL)**

Mfd by HIKMA FARMACÊUTICA (PORTUGAL), SA
Made in Portugal
Dist by Hikma Pharmaceuticals USA Inc.
Berkeley Heights, NJ 07922



(01)00301439318019

PLB191-WES/2

Lot:

Exp:

For Intravenous Infusion ONLY



**Principal Display Panel 51662-1528-2
Pouch**

**NOREPINEPHRINE BITARTRATE INJECTION,
USP 4mg PER 4mL (1 mg/mL) 4mL VIAL**

NDC: 51662-1528-2
LOT: 123456
EXP: 2030-01-01

(01) 00351662152829
(10) 123456
(17) 300101
(21) 51766500438

FOR IV INFUSION ONLY. DILUTE BEFORE USE. PROTECT FROM LIGHT.
WARNING: CONTAINS SULFITES, THIS IS A POTENT DRUG. DOSAGE
SHOULD BE CONTROLLED BY FREQUENT DETERMINATION OF BP. AVOID
EXTRAVASATION. USUAL DOSAGE: READ PACKAGE INSERT. EACH mL
CONTAINS NOREPINEPHRINE BITRATE, EQUIVALENT TO 1 mg
NOREPINEPHRINE BASE, NaCl FOR ISOTONICITY WITH NOT MORE THAN
0.2mg OF SODIUM METABISULFITE AS ANTIOXIDANT. AIR IN THE VIALS
HAS BEEN DISPLACED BY NO₂ GAS. DO NOT USE THE SOLUTION IF ITS
COLOR IS PINKISH OR DARKER THAN SLIGHTLY YELLOW OR IF IT
CONTAINS A PRECIPITATE. AVOID CONTACT WITH IRON SALTS,
ALKALIS, OR OXIDIZING AGENTS. STORE AT 20°-25°C (68°-77°F);
EXCURSIONS PERMITTED TO 15°-30°C (59°-86°F) [SEE USP CONTROLLED
ROOM TEMP.]

See manufacturer's package insert

ORIGINAL MFG NDC: 0143-9318-10

RX ONLY

Manufactured by HF Acquisition Co., LLC
Mukilteo, WA 98275



NDC 0143-9318-01

Rx only

4 mL Single Dose Vial

**Norepinephrine
Bitartrate Injection, USP**

Each mL contains norepinephrine bitartrate
equal to 1 mg norepinephrine base.

**DILUTE BEFORE USE. Protect from light.
Warning: Contains Sulfites.**

**4 mg per 4 mL
(1 mg/mL)**

Mfd by HIKMA FARMACÊUTICA (PORTUGAL), SA
Made in Portugal
Dist by Hikma Pharmaceuticals USA Inc.
Berkeley Heights, NJ 07922



(01)00301439318019

PLB191-WES/2

Lot:

Exp:

For Intravenous Infusion ONLY

**Principal Display Panel 51662-1528-3
Case Labeling**

(01) 00551662152896
(17) 300101
(21) 136194854035
(10) 123456



See manufacturer's package insert
Distributed by HF Acquisition Co., LLC
Mukilteo, WA 98275

RX ONLY

**NOREPINEPHRINE BITARTRATE INJECTION,
USP 4mg PER 4mL (1 mg/mL) 4mL VIAL (CASE OF
10)**

NDC: 51662-1528-3
LOT: 123456
EXP: 2030-01-01

(01) 00351662152836
(10) 123456
(17) 300101
(21) 136194854035

CASE

FOR IV INFUSION ONLY. DILUTE BEFORE USE. PROTECT FROM LIGHT.
WARNING: CONTAINS SULFITES, THIS IS A POTENT DRUG. DOSAGE
SHOULD BE CONTROLLED BY FREQUENT DETERMINATION OF BP. AVOID
EXTRAVASATION. USUAL DOSAGE: READ PACKAGE INSERT. EACH mL
CONTAINS NOREPINEPHRINE BITRATE, EQUIVALENT TO 1 mg
NOREPINEPHRINE BASE, NaCl FOR ISOTONICITY WITH NOT MORE THAN
0.2mg OF SODIUM METABISULFITE AS ANTIOXIDANT. AIR IN THE VIALS
HAS BEEN DISCALCED BY NO₂ GAS. DO NOT USE THE SOLUTION IF ITS
COLOR IS PINKISH OR DARKER THAN SLIGHTLY YELLOW OR IF IT
CONTAINS A PRECIPITATE. AVOID CONTACT WITH IRON SALTS,
ALKALIS, OR OXIDIZING AGENTS. STORE AT 20°-25°C (68°-77°F);
EXCURSIONS PERMITTED TO 15°-30°C (59°-86°F) [SEE USP CONTROLLED
ROOM TEMP.]

See manufacturer's package insert

ORIGINAL MFG NDC: 0143-9318-10

RX ONLY

Manufactured by HF Acquisition Co., LLC

Mukilteo, WA 98275



NOREPINEPHRINE BITARTRATE

norepinephrine bitartrate injection

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:51662-1528(NDC:0143- 9318)
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
NOREPINEPHRINE BITARTRATE (UNII: IFY5PE3ZRW) (NOREPINEPHRINE - UNII:X4W3ENH1CV)	NOREPINEPHRINE	1 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X)	
WATER (UNII: 059QF0KO0R)	
SODIUM METABISULFITE (UNII: 4VON5FNS3C)	
NITROGEN (UNII: N762921K75)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51662-1528-1	4 mL in 1 VIAL; Type 0: Not a Combination Product	08/08/2021	
2	NDC:51662-1528-3	10 in 1 CASE	07/10/2022	
2	NDC:51662-1528-2	1 in 1 POUCH		
2		4 mL in 1 VIAL; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA203662	08/08/2021	

Labeler - HF Acquisition Co LLC, DBA HealthFirst (045657305)

Registrant - HF Acquisition Co LLC, DBA HealthFirst (045657305)

Establishment

Name	Address	ID/FEI	Business Operations
HF Acquisition Co LLC, DBA HealthFirst		045657305	relabel(51662-1528)

Revised: 7/2022

HF Acquisition Co LLC, DBA HealthFirst